MSD announced that David Peacock will succeed Louise Houson as Managing Director of MSD in the UK and Ireland from October 1st 2019.
David Peacock will bring a broad range of experience and perspectives from senior roles with the company in the United States, Singapore, Vietnam, and Japan. Most recently, David was the Chief of Staff to Kenneth C. Frazier, Chairman of the board and chief executive officer, Merck & Co., Inc., Kenilworth, N.J. (known as MSD outside the U.S. and Canada). He has also held other significant roles within the company as Managing Director of Hong Kong and Macau and the Chief Financial Officer for MSD in Japan.
David said: “I am delighted to have been appointed MD of MSD in the UK and Ireland. MSD has both a rich heritage and continued focus on scientific invention of medicines and vaccines to improve the health and wellbeing of populations and patients. I am honoured to have this leadership role and humbled to continue MSD’s legacy here. We know we can’t solve today and tomorrow’s healthcare challenges alone, and I am looking forward to working with our team to build on our existing relationships with partners so that our innovations reach as many eligible patients as possible in the UK.”
Louise Houson, who has held the post of MD for MSD in the UK and Ireland for the past three years, will be taking on a leadership role in MSD’s global vaccines organization in the U.S.